Gain Therapeutics Dividend
Dividend criteria checks 0/6
Gain Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 2.9% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | -US$1.23 |
Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Jan 12Gain Therapeutics appoints CEO
Sep 20Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Oct 27Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Aug 19Gain Therapeutics EPS misses by $0.29
May 10Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if GANX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GANX's dividend payments have been increasing.
Dividend Yield vs Market
Gain Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (GANX) | n/a |
Market Bottom 25% (US) | 1.6% |
Market Top 25% (US) | 4.8% |
Industry Average (Biotechs) | 2.9% |
Analyst forecast in 3 Years (GANX) | n/a |
Notable Dividend: Unable to evaluate GANX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GANX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate GANX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GANX has not reported any payouts.